Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 2/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.49 |
| ▸ | BCL2 | P10415 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846081 | 0.96 | PLA2G4A (0.61) | PLA2G4APLGPLAUHCAR3NR1H2 | |
| SCHEMBL7340362 | 0.94 | PLA2G4A (0.63) | PLA2G4APLGPLAUHCAR3NR1H2 | |
| SCHEMBL4934703 | 0.91 | PLA2G4A (0.55) | PLA2G4APLGPLAUHCAR3NR1H2 | |
| SCHEMBL3351795 | 0.88 | MCL1 (0.61) | PLA2G4AHCAR3MCL1BCL2 | |
| SCHEMBL4813289 | 0.85 | PLG (0.55) | PLA2G4APLGPLAUNR1H2PPARA | |
| SCHEMBL6754275 | 0.85 | PLG (0.51) | PLA2G4APLGPLAUMCL1BCL2 | |
| SCHEMBL2932437 | 0.85 | MCL1 (0.55) | PLA2G4APLGPLAUHCAR3NR1H2 | |
| SCHEMBL3349233 | 0.85 | PLG (0.51) | PLA2G4APLGPLAU | |
| SCHEMBL5387474 | 0.84 | TUBB4A (0.59) | PLA2G4APLGPLAUHCAR3 | |
| SCHEMBL9034120 | 0.84 | PLG (0.48) | PLA2G4APLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| CN-100506792-C | Substituted N-aryl heterocycles, method for the production thereof and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2009-07-01 | — | — | CN | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| CN-1774418-A | Substituted N-arylheterocycles, method for production and use thereof as medicaments | AVENTIS PHARMA GMBH (DE) | 2006-05-17 | — | — | CN | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1590324-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2005-11-02 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004069797-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A2 | MERCKLE GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | PLA2G4A 3594/4885PLG 2813/4885PLAU 3907/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | PLA2G4A 3690/4885PLG 2306/4885PLAU 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.